Erlocip 150mg Tablet (Erlotinib HCl) is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor approved for treating EGFR mutation-positive non-small cell lung cancer (NSCLC). Composition: Each tablet contains 150mg Erlotinib hydrochloride with pharmaceutical excipients. Indications: Erlotinib treats locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 (L858R) mutations; first-line therapy for EGFR-mutant disease; maintenance therapy post-chemotherapy in EGFR-wild-type NSCLC; pancreatic cancer in combination with gemcitabine. Clinical efficacy demonstrates significantly improved progression-free survival (9-13 months) versus chemotherapy in mutation-positive patients. Contraindications: Absolute contraindications include hypersensitivity to erlotinib, severe hepatic impairment, and concurrent use of strong CYP3A4 inducers. Relative caution with baseline lung disease, severe renal impairment, or GI disorders. Drug Interactions: Major interactions with CYP3A4 inducers (rifampin, carbamazepine reduce levels), CYP3A4 inhibitors (ketoconazole increase levels), and antacids (separate dosing by 2 hours). Warfarin requires INR monitoring. Dosage & Administration: Standard dosing is 150mg once daily on empty stomach; can reduce to 100mg or increase to 200mg based on tolerability. Take 1 hour before/2 hours after meals for optimal absorption. Storage: 15-30°C in original moisture-protective packaging. Side Effects: Common: diarrhea (50-70%), rash/acneiform dermatitis (75-90%), stomatitis, anorexia, fatigue. Serious: interstitial lung disease (1-2%), hepatotoxicity, GI perforation, severe diarrhea-induced dehydration. Precautions & Warnings: Baseline and monthly LFTs mandatory; baseline and periodic chest imaging for ILD monitoring; aggressive diarrhea prophylaxis with loperamide; infection screening essential; skin care protocol important. Pregnancy & Lactation: Erlotinib is teratogenic (Category D); absolutely contraindicated in pregnancy and breastfeeding. Males require barrier contraception during therapy. Females require hormonal contraception plus barrier methods with pregnancy testing baseline and monthly. Substitutes & Alternatives: First-generation EGFR TKIs (Gefitinib, Afatinib) for EGFR-mutant NSCLC; second-generation agents (Dacomitinib, Osimertinib) for T790M-resistant disease; chemotherapy for wild-type EGFR patients. FAQs: Expected response time 4-8 weeks; diarrhea management strategies (dietary modification, antidiarrheals); cost and insurance coverage considerations; treatment duration until progression. Expected Timeline: Week 4 tolerability assessment; Week 8 CT imaging evaluation; Month 3 response confirmation via RECIST; ongoing monthly clinical monitoring. Book Thoracic Oncology Consultation: Essential for EGFR mutation testing, therapy optimization, toxicity management, and disease surveillance protocols. Schedule Tests: Baseline CBC, LFTs, renal function; monthly LFTs initially then quarterly; baseline and monthly chest X-ray/CT; monthly assessment for diarrhea and GI symptoms; baseline and periodic ECG if applicable.